In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC
Tweet Content
In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC (ADeodhar et al)
⬆️freq AEs: nasopharyngitis & URTI
Low EAIRs/100pt yrs for IBD, malignancies & MACE
No new safety signals
Reassuring data.
#ACR23 ABST1436 @RheumNow https://t.co/guF0gC4hQM
Show on Archive Page
On
Display in Search Results
On
PDQ
Off